Skip to main content
. Author manuscript; available in PMC: 2011 Mar 2.
Published in final edited form as: J Urol. 2010 Oct 16;184(6):2313–2319. doi: 10.1016/j.juro.2010.08.012

Table 6.

Incidence of other cardiovascular related treatment emergent AEs

No. Degarelix 240/80 mg (%) No. Degarelix 240/160 mg (%) No. Pooled Degarelix (%) No. Leuprolide 7.5 mg (%)
Ischemic heart disease 8 (4) 10 (5) 18 (4) 21 (10)
Peripheral vascular atherosclerosis 3 (1) 2 (1) 5 (1) 1 (less than 1)
Cerebrovascular disease 5 (2) 2 (1) 7 (2) 1 (less than 1)
Cardiac failure 2 (1) 3 (1) 5 (1) 5 (2)